title: [Innovative treatment in oncology].
abstract: The improved knowledge of the key molecular mechanisms involved in cell transformation and tumor progression allows to the identification of new therapeutic targets for anticancer therapy. Several molecular-targeting compounds have been developed, capable to selectively interfire with tumorangiogenesis, receptors with tyrosin-chinase activity, specific tumor growth factors. A rationale selection of the patients as well as an appropriate monitoring of pharmacodynamics effects of molecular-targeting compounds need of the availability of surrogate markers, assessable in tumor tissue of circulating blood.
authors.affiliation: Unità Operativa di Oncologia Medica, Azienda Complesso Ospedaliero di Rilevanza Nazionale San Filippo Neri, Roma.
authors.forename: Barbara
authors.initials: B
authors.lastname: Capaccetti
authors.forename: Paola
authors.initials: P
authors.lastname: Bonginelli
authors.forename: Roberta
authors.initials: R
authors.lastname: Sarmiento
authors.forename: Massimo
authors.initials: M
authors.lastname: Fanelli
authors.forename: Raffaele
authors.initials: R
authors.lastname: Longo
authors.forename: Domenico
authors.initials: D
authors.lastname: Gattuso
authors.forename: Giampietro
authors.initials: G
authors.lastname: Gasparini
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015363:Quinolones / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D015363:Quinolones; D011505:Protein-Tyrosine Kinases; C402769:tipifarnib